We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What Is Transthyretin Amyloidosis?

Mary McMahon
Updated Mar 03, 2024
Our promise to you
The Health Board is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At The Health Board, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject-matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Transthyretin amyloidosis is an inherited condition that causes a buildup of abnormal proteins in the body called amyloids. They can start to interfere with the function of the patient’s nervous system, causing progressive symptoms. Age at onset can range from 20 to 70, depending on the specific mutations involved, and tends to be earlier in people who come from regions with a long history of the disease, like Portugal and Japan. Treatment options are available and tend to be most effective when provided early.

This condition occurs as a result of an error with the encoding of a protein called transthyretin, which is normally produced in the liver. It normally acts as a transporter for vitamin A and thyroid hormone, and starts carrying amyloid deposits to the nervous system, where they build up over time. There are three forms of the disease: leptomeningeal, peripheral, and cardiac. These forms are named for the different areas of the body they affect.

In patients with leptomeningeal transthyretin amyloidosis, the amyloids build up in the central nervous system, while peripheral patients experience symptoms in the peripheral nervous system like numbness, tingling, and loss of motor control. Cardiac forms attack the heart muscle and cause an irregular heartbeat. Some testing can determine which form a patient has and identify the rogue proteins responsible to learn more about the origins of the condition.

Some medications are available to treat patients with transthyretin amyloidosis. Another option is a liver transplant, especially if it is provided early. The new liver doesn’t carry the defective gene and should code the transthyretin correctly. In patients with existing amyloidosis, it won’t be possible to reverse the effects, but the progression of the disease may stop. Other patients may continue to experience problems, as the amyloids can continue to build up without a carrier protein in some instances.

The gene for this condition is dominant. Someone only needs to inherit one copy in order to express it, and a parent with the disease has a 50% chance of passing it to a child, or a 100% chance if that parent happens to carry two copies of the gene. Parents concerned about transthyretin amyloidosis can meet with a genetic counselor to get more information about their options. This can include some testing to find out more about their genetics, as this could provide helpful insights into how to manage risks of genetic diseases like transthyretin amyloidosis in children.

The Health Board is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Mary McMahon
By Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a The Health Board researcher and writer. Mary has a liberal arts degree from Goddard College and spends her free time reading, cooking, and exploring the great outdoors.

Discussion Comments
Mary McMahon
Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a...

Learn more
The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.

The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.